Advertisement
Corrigendum Free access | 10.1172/JCI125184
Find articles by Rodrigues, D. in: JCI | PubMed | Google Scholar
Find articles by Rescigno, P. in: JCI | PubMed | Google Scholar
Find articles by Liu, D. in: JCI | PubMed | Google Scholar
Find articles by Yuan, W. in: JCI | PubMed | Google Scholar
Find articles by Carreira, S. in: JCI | PubMed | Google Scholar
Find articles by Lambros, M. in: JCI | PubMed | Google Scholar
Find articles by Seed, G. in: JCI | PubMed | Google Scholar
Find articles by Mateo, J. in: JCI | PubMed | Google Scholar
Find articles by Riisnaes, R. in: JCI | PubMed | Google Scholar
Find articles by Mullane, S. in: JCI | PubMed | Google Scholar
Find articles by Margolis, C. in: JCI | PubMed | Google Scholar
Find articles by Miao, D. in: JCI | PubMed | Google Scholar
Find articles by Miranda, S. in: JCI | PubMed | Google Scholar
Find articles by Dolling, D. in: JCI | PubMed | Google Scholar
Find articles by Clarke, M. in: JCI | PubMed | Google Scholar
Find articles by Bertan, C. in: JCI | PubMed | Google Scholar
Find articles by Crespo, M. in: JCI | PubMed | Google Scholar
Find articles by Boysen, G. in: JCI | PubMed | Google Scholar
Find articles by Ferreira, A. in: JCI | PubMed | Google Scholar
Find articles by Sharp, A. in: JCI | PubMed | Google Scholar
Find articles by Figueiredo, I. in: JCI | PubMed | Google Scholar
Find articles by Keliher, D. in: JCI | PubMed | Google Scholar
Find articles by Aldubayan, S. in: JCI | PubMed | Google Scholar
Find articles by Burke, K. in: JCI | PubMed | Google Scholar
Find articles by Sumanasuriya, S. in: JCI | PubMed | Google Scholar
Find articles by Fontes, M. in: JCI | PubMed | Google Scholar
Find articles by Bianchini, D. in: JCI | PubMed | Google Scholar
Find articles by Zafeiriou, Z. in: JCI | PubMed | Google Scholar
Find articles by Mendes, L. in: JCI | PubMed | Google Scholar
Find articles by Mouw, K. in: JCI | PubMed | Google Scholar
Find articles by Schweizer, M. in: JCI | PubMed | Google Scholar
Find articles by Pritchard, C. in: JCI | PubMed | Google Scholar
Find articles by Salipante, S. in: JCI | PubMed | Google Scholar
Find articles by Taplin, M. in: JCI | PubMed | Google Scholar
Find articles by Beltran, H. in: JCI | PubMed | Google Scholar
Find articles by Rubin, M. in: JCI | PubMed | Google Scholar
Find articles by Cieslik, M. in: JCI | PubMed | Google Scholar
Find articles by Robinson, D. in: JCI | PubMed | Google Scholar
Find articles by Heath, E. in: JCI | PubMed | Google Scholar
Find articles by Schultz, N. in: JCI | PubMed | Google Scholar
Find articles by Armenia, J. in: JCI | PubMed | Google Scholar
Find articles by Abida, W. in: JCI | PubMed | Google Scholar
Find articles by Scher, H. in: JCI | PubMed | Google Scholar
Find articles by Lord, C. in: JCI | PubMed | Google Scholar
Find articles by D’Andrea, A. in: JCI | PubMed | Google Scholar
Find articles by Sawyers, C. in: JCI | PubMed | Google Scholar
Find articles by Chinnaiyan, A. in: JCI | PubMed | Google Scholar
Find articles by Alimonti, A. in: JCI | PubMed | Google Scholar
Find articles by Nelson, P. in: JCI | PubMed | Google Scholar
Find articles by Drake, C. in: JCI | PubMed | Google Scholar
Find articles by Van Allen, E. in: JCI | PubMed | Google Scholar
Find articles by de Bono, J. in: JCI | PubMed | Google Scholar
Published November 1, 2018 - More info
BACKGROUND. Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS. Defective mismatch repair (dMMR) status was determined by either loss of mismatch repair protein expression on IHC or microsatellite instability (MSI) by PCR in 127 APC biopsies from 124 patients (Royal Marsden [RMH] cohort); MSI by targeted panel next-generation sequencing (MSINGS) was then evaluated in the same cohort and in 254 APC samples from the Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF). Whole exome sequencing (WES) data from this latter cohort were analyzed for pathogenic MMR gene variants, mutational load, and mutational signatures. Transcriptomic data, available for 168 samples, was also performed. RESULTS. Overall, 8.1% of patients in the RMH cohort had some evidence of dMMR, which associated with decreased overall survival. Higher MSINGS scores associated with dMMR, and these APCs were enriched for higher T cell infiltration and PD-L1 protein expression. Exome MSINGS scores strongly correlated with targeted panel MSINGS scores (r = 0.73, P < 0.0001), and higher MSINGS scores associated with dMMR mutational signatures in APC exomes. dMMR mutational signatures also associated with MMR gene mutations and increased immune cell, immune checkpoint, and T cell–associated transcripts. APC with dMMR mutational signatures overexpressed a variety of immune transcripts, including CD200R1, BTLA, PD-L1, PD-L2, ADORA2A, PIK3CG, and TIGIT. CONCLUSION. These data could impact immune target selection, combination therapeutic strategy selection, and selection of predictive biomarkers for immunotherapy in APC. FUNDING. We acknowledge funding support from Movember, Prostate Cancer UK, The Prostate Cancer Foundation, SU2C, and Cancer Research UK.
Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B. Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane, Claire Margolis, Diana Miao, Susana Miranda, David Dolling, Matthew Clarke, Claudia Bertan, Mateus Crespo, Gunther Boysen, Ana Ferreira, Adam Sharp, Ines Figueiredo, Daniel Keliher, Saud Aldubayan, Kelly P. Burke, Semini Sumanasuriya, Mariane Sousa Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Larissa Sena Teixeira Mendes, Kent Mouw, Michael T. Schweizer, Colin C. Pritchard, Stephen Salipante, Mary-Ellen Taplin, Himisha Beltran, Mark A. Rubin, Marcin Cieslik, Dan Robinson, Elizabeth Heath, Nikolaus Schultz, Joshua Armenia, Wassim Abida, Howard Scher, Christopher Lord, Alan D’Andrea, Charles L. Sawyers, Arul M. Chinnaiyan, Andrea Alimonti, Peter S. Nelson, Charles G. Drake, Eliezer M. Van Allen, Johann S. de Bono
Original citation: J Clin Invest. 2018;128(10):4441–4453. https://doi.org/10.1172/JCI121924
Citation for this corrigendum: J Clin Invest. 2018;128(11):5185. https://doi.org/10.1172/JCI125184
Charles L. Sawyers’s conflict-of-interest statement was not included in the manuscript. The correct statement is below.
CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014.
The authors regret the error.